HomeLSTA • NASDAQ
add
Lisata Therapeutics Inc
Previous close
$2.68
Day range
$2.63 - $2.95
Year range
$2.19 - $4.20
Market cap
22.16M USD
Avg Volume
64.78K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 5.34M | -10.53% |
Net income | -4.93M | 6.29% |
Net profit margin | — | — |
Earnings per share | -0.59 | 9.23% |
EBITDA | -5.29M | 10.53% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 35.86M | -34.08% |
Total assets | 38.20M | -34.24% |
Total liabilities | 4.76M | -11.55% |
Total equity | 33.44M | — |
Shares outstanding | 8.39M | — |
Price to book | 0.66 | — |
Return on assets | -33.03% | — |
Return on capital | -37.14% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -4.93M | 6.29% |
Cash from operations | -2.52M | 29.72% |
Cash from investing | -6.30M | -151.46% |
Cash from financing | 0.00 | 100.00% |
Net change in cash | -8.78M | -200.53% |
Free cash flow | -857.00K | 47.89% |
About
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Founded
1980
Headquarters
Website
Employees
25
